

## **Astellas Submits Additional Indication Application for Hypnosedative, Dormicum® in Japan**

Tokyo, February 20 2013 - [Astellas Pharma Inc.](#) (“Astellas”; Tokyo:4503; President and CEO: Yoshihiko Hatanaka) announced that it has submitted today an additional indication application for “conscious sedation in dentistry and dental surgery”, for hypnosedative, Dormicum® Injection 10mg (generic name: midazolam) in Japan. The application is based on published evidence in accordance with the "Handling of Ethical Drugs for Off-label Use", Notification No. 4 of the Research and Development Division / Notification No. 104 of the Evaluation and Licensing Division, dated February 1, 1999..

### Product Overview and Application Details

Product Name: Dormicum® Injection 10mg

Generic Name: Midazolam

Indications: (The additional indication related to this application is underlined)

Anesthetic premedication  
Introduction and maintenance of general anesthesia  
Sedation during artificial respiration in critical care  
Conscious sedation in dentistry and dental surgery

###

For inquiries or additional information

Astellas Pharma Inc.

Corporate Communications

TEL: +81-3-3244-3201, FAX:+81-3-5201-7473

<http://www.astellas.com/en>